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Abstract
Gallid alphaherpesvirus 1 (syn. infectious laryngotracheitis virus; ILTV) is the causative agent of infectious laryngotrachei-
tis, a respiratory disease of chickens causing substantial economic losses in the poultry industry every year. Currently, 
the most efficient way to achieve protection against infection is immunization with live-attenuated vaccines. However, this 
vaccination strategy entails the risk of generating new pathogenic viruses resulting from spontaneous mutations or from 
recombination with field strains. This work presents a new approach based on virus-like particles (VLPs) displaying ILTV 
glycoproteins B (gB) or G (gG) on their surface. The main focus of this pilot study was to determine the tolerability of V
LPs delivered in ovo and intramuscularly (i.m.) into chickens and to investigate the nature of the immune response elic-
ited. The study revealed that the new vaccines were well tolerated in hybrid layer chicks independent of the administra-
tion method (in ovo or i.m.). Upon in ovo injection, vaccination with VLP-gG led to an antibody response, while a cellular 
immune response in VLP-gB-immunized chickens was hardly detectable. Since the administration of VLPs had no visible 
side effects in vivo and was shown to elicit an antibody-based immune response, we anticipate that VLPs will become a 
valuable platform for the development of new safe vaccines for poultry.
InTRoduCTIon
Infectious laryngotracheitis (ILT) is a worldwide respira-
tory disease of chickens. The causative agent is the Gallid 
alphaherpesvirus 1 also known as infectious laryngotra-
cheitis virus (ILTV), which mainly infects chickens, but 
has also been detected in pheasants, peafowls and turkeys 
[1–3]. The clinical signs caused by ILTV range from 
reduced general conditions with mild nasal discharge, 
conjunctivitis and tracheitis, to serious clinical condi-
tions with discharge of bloody mucus caused by severe 
laryngotracheitis, leading to dyspnoea and eventually to 
death by suffocation [4]. Depending on the virus strain, 
mortality among infected chickens varies from 10 to 
70 %. Improvement of safety measures to prevent ILTV 
infections in chicken farms is urgently needed in order to 
address animal welfare issues and to reduce high annual 
economic loss. The latter is mainly due to milder forms 
of ILT resulting in egg drop in laying hens and decreased 
weight gain in broilers [4].
Currently, several vaccines are available. The most efficient 
ones are based on live attenuated viruses of tissue culture 
(TCO) or of chicken embryo origin (CEO). Despite providing 
robust protection in most instances, these vaccines bear the 
risk of reversion or recombination with other vaccine or field 
strains of ILTV, potentially resulting in novel and more viru-
lent variants [5–7]. Recently, vectored vaccines were devel-
oped based on either the fowlpox virus or the herpesvirus 
of turkey, engineered to express ILTV glycoprotein B (gB) 
and UL32 (CEVA, vectormune FP LT) or glycoproteins I (gI) 
and D (gD) (Intervet/Merck Animal Health, INNOVAX-ILT), 
respectively [8–11]. Because these vectored vaccines are based 
on low-pathogenicity or apathogenic chicken viruses, there 
is no risk of reversion or recombination to virulent variants. 
Nonetheless, these engineered vaccines are replication compe-
tent, and thus retain the potential of accumulating mutations, 
possibly leading to undesired effects. Furthermore, vectored 
vaccines reduce clinical signs, but are not able to suppress 
replication of challenge virus in the trachea of experimentally 
infected chickens [12]. Other approaches use affinity purified 
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gB or bicistronic plasmid vectors expressing gB and chicken 
interleukin 18 (ChIL-18) [13, 14]. Even though the published 
results look promising, no further developments have been 
reported to date.
Another possibility, not yet applied in ILT vaccination 
strategies, is the engineering of virus-like particles (VLPs). 
Membrane-enveloped VLPs can be specifically modified 
to present heterologous antigens in high densities on their 
surface. In contrast to the aforementioned vaccine strategies, 
VLPs are not infectious, do not replicate and do not contain 
any genetic material. VLPs are thus a very safe vaccine plat-
form. In addition, VLPs have the potential to stimulate an 
immune response on various levels. Due to their origin, they 
resemble the highly organized and repetitive symmetry of the 
virus from which they are derived. These features are impor-
tant for efficient activation of B cells [15] and allow efficient 
binding of natural IgM antibodies, which in turn activate 
the classic complement cascade [16]. Moreover, VLPs are 
efficiently taken up by antigen-presenting cells (APCs). VLP 
shape, surface charge, hydrophobicity and hydrophilicity, 
but also their size (20–100 nm), mediate improved uptake 
into APCs as compared to smaller (<10 nm) affinity-purified 
proteins used as subunit vaccines [17]. Soluble proteins are 
inefficiently taken up by APCs and are usually only presented 
on MHC class II molecules leading to the activation of CD4+ 
T cells. In contrast, VLPs are degraded into peptides in APCs 
and can be cross-presented on MHC class I and on MHC 
class II molecules, thus resulting not only in the stimulation 
of CD4+ T cells but also CD8+ T cells [18]. In summary, VLPs 
are a powerful tool to stimulate the innate immune system as 
well as a humoral and cellular immune response.
In this report, VLPs based on the murine leukaemia virus 
(MLV) were engineered to present either ILTV gB or ILTV gG 
on their surfaces. Among herpesviruses, gB is highly conserved 
[19] and was shown to elicit humoral as well as cell-mediated 
immunity [20, 21]. ILTV gB has already been tested in various 
vaccination approaches and been shown to confer protective 
immunity [12–14, 22–24]. Because cellular immunity is of 
particular importance to combat ILTV infection [25–29], 
VLPs-gB were further modified by maleylation. Maleylated 
proteins are directed to scavenger receptors present on APCs, 
and thus are able to induce a more dominant cellular immune 
response, which in turn leads to decreased levels of IgM and 
IgG [30–32]. To further boost the cell-mediated immunity 
in vaccinated chickens, either plasmids mediating expression 
of ChIL-18 were administered together with the VLPs, or in 
a second approach, VLPs displaying ILTV gG were admin-
istered together with ChIL-2. In the latter, it was anticipated 
to provoke a humoral immune response to counteract gG. 
This is important, because gG initiates an immune evasion 
mechanism by directing the cell-mediated immune response 
toward an antibody-mediated immune response [33, 34].
In this pilot study, VLPs were used for the first time as 
vaccines against ILTV in layer chickens. Thus, the main focus 
was put on examining the tolerability of the VLPs in chickens 
upon different inoculation methods [in ovo or intramuscular 
(i.m.)]. For animal welfare considerations, no challenge 
experiments were performed at this stage. However, immune 
responses upon vaccination were measured and shed light 
on the mechanisms mediating potential protection against 
infection with ILTV.
METHodS
Plasmid construction
For the construction of pDisplay (Invitrogen, Thermo 
Fisher Scientific)-based expression vectors, two different 
ILTV glycoprotein regions were chosen: amino acids (aa) 2 
to 700 from gB and aa 30 to 293 from gG as illustrated in 
Fig. 1. Cloning of the gB expression construct (pDgB700) 
was outsourced to GeneArt Gene Synthesis Services (Thermo 
Fisher). To generate pDgGΔ1–29, an 848 bp DNA fragment 
Fig. 1. Schematic illustration of the display constructs and the respective coding regions of the ILTV glycoprotein variants. The pDisplay 
expression plasmid encodes for the leader sequence (LS), HA and Myc tags and the transmembrane domain of the PDGF receptor 
(PDGFR TM). Below is a scheme of the wild type proteins (gB, gG) and of the coding regions that were inserted into pDisplay (gB700, 
gGΔ1–29), both of which contained a His tag. Respective amino acid numbers are indicated. TM, transmembrane domain; SS, signal 
sequence.
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encompassing the respective part of gG was amplified using 
PCR and oligonucleotides gG_Bgl(+) and gG_Pst(-). ILTV 
DNA (ILTV strain 489; a kind gift from W. Fuchs and 
T. Mettenleiter [35]) served as template.
For construction of ChIL-2 and ChIL-18 expression plasmids, 
the respective sequences were amplified using oligonucleo-
tides ChIL-2(+), ChIL-2(-)2, ChIL-18(+)2 and ChIL-18(-)2. 
Chicken spleen cDNA (Amsbio) served as template. The 
respective amplicons were inserted into the pcDNA3_3 
TOPO vector (Invitrogen, Thermo Fisher) downstream of 
the cytomegalovirus (CMV) promoter resulting in constructs 
pcDNA-ChIL-2-His and pcDNA-ChIL-18-His. Using these 
two plasmids as templates, ChIL-2 and ChIL-18 encoding 
sequences were amplified using oligonucleotides EcoChIL-
2(+), EcoChIL-2(-), XhoChIL-18 and XhoChIL15.18(-). The 
amplicons were ligated into the pCAGGS vector (kind gift 
from J. Miyazaki [36]) resulting in pCAGGS-ChIL-2-His and 
pCAGGS-ChIL-18-His. Plasmids were isolated from bacteria 
using the GenElute HP Endotoxin-Free Plasmid Kit (Sigma 
Aldrich). Endotoxin levels were determined using the Toxin-
Sensor Chromogenic LAL Endotoxin Assay Kit (GenScript).
The MLV gag expression construct pcGag was constructed 
by amplifying the 1617 bp gag encoding sequence using 
oligonucleotides gag(+) and gag(-) and subsequent insertion 
into the pcDNA3_3 TOPO vector (Invitrogen, Thermo Fisher 
Scientific). The plasmid pHit60 [37] served as a template. 
All primers were synthesized by Microsynth (sequences are 
shown in Table 1).
Gene transcription of ChIL-2 and ChIL-18
To detect ChIL-2 and ChIL-18, RNA was isolated from chicken 
cells [leghorn male hepatoma (LMH), Cell Lines Service] 48 
h after transfection or from blood and organ samples from 
chicks using the NucleoSpin RNA Kit (Macherey Nagel). 
RNA served as template for real-time RT-PCR performed 
as previously described by Kaiser et al. (ChIL-2) and Kogut 
et al. (ChIL-18) [38, 39]. In parallel, chicken GAPDH was 
amplified and used for normalization (avGAPDH_for 
GGAGTCAACGGATTTGGCC, avGAPDH_rev TTTGC-
CAGAGAGGACGGC, avGAPDH_probe FAM- TATT GGCC 
GCCT GGTC ACCAGG-TAMRA). In brief, the reaction 
mixture consisted of 12.5 µl QuantiTect Probe RT-PCR Master 
Mix (Qiagen), 5 µl isolated RNA, 400 nM oligonucleotides, 
10 nM probe and 0.25 µl QuantiTect RT Mix in a total 
volume of 25 µl. Amplification and detection were performed 
using the 7500 Fast Real-Time PCR System (Thermo 
Fisher Scientific) with the following cycle conditions: 
50 °C for 30 min, 95 °C for 5 min, and 40 cycles of 95 °C for 
20 s, 60 °C for 1 min and 72 °C for 1 min.
Production of ILTV gB- and ILTV gG-displaying VLPs
LMH cells were cultivated in 10 cm dishes in Waymouth’s 
medium supplemented with 10 % FBS at 38 °C and 5 % 
CO2. When cultured cells reached appropriate confluency, 
co-transfection with pcGag (7 µg per dish) and pDgB700 
(8 µg per dish) or pDgGΔ1–29 (8 µg per dish), respectively, 
was conducted under serum-free conditions employing 
TransIT−2020 (Mirus) according to the manufacturer’s 
instructions. The VLP-containing cell culture supernatants 
were harvested 48 h later and subsequently passed through 
a 0.45 µm pore-size polyethersulfone filter (Sarstedt). VLPs 
were concentrated by ultracentrifugation (Rav 150 000 g, 3 h, 
4 °C) through a 20 % sucrose cushion. The pelleted VLPs were 
resuspended in an appropriate amount of PBS.
Maleylation of VLP-gB
VLPs displaying ILTV gB were further modified by adding 
maleyl groups as previously described by Butler and Hartley 
Table 1. Oligonucleotides used for cloning
Bold type: restriction sites (BglI, PstI, EcoRI, XhoI); underlined: 6x His-tag.
Oligo name Oligo sequence 5′→3′
gG_Bgl(+) GTAGAGATCTCACCATCATCATCACCACGCTAGCGCACTGGACGGGCTCGAGTC
gG_Pst(-) GACTCTGCAGCCTTCCCTCGATCTGCTGGAGCGTAGAGGGCGGTGAAAAG
ChIL-2(+)2 ATGATGTGCAAAGTACTGATCTTTGGCTGTATTTCGGTAGCAATGC
ChIL-2(-)2 TTAATGGTGATGGTGATGGTGTTTTTGCAGATATCTCACAAAGTTGG
ChIL-18(+)2 ATGAGCTGTGAAGAGATCGCAGTGTGTGCAGTACGGCTTAGAG
ChIL-18(-)2 TCAATGGTGATGGTGATGGTGTAGGTTGTGCCTTTCATTATG
EcoChIL-2(+) GCAAAGAATTCATGATGTGCAAAGTACTG
EcoChIL-2(-) GGAGTGAATTCTTAATGGTGATGGTGATG
XhoChIL-18(+) AATTCCTCGAGATGAGCTGTGAAGAGATCGC
XhoChIL15.18(-) AATTCCTCGAGTTAATGGTGATGGTGATG
gag(+) ATGGGCCAGACTGTTACCA
gag(-) CTAGTCATCTAGGGTCAGGAG
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[40]. In brief, VLPs were dissolved in carbonate-bicarbonate 
buffer (CB; 0.1 M Na2CO3, 0.1 M NaHCO3, pH 8.5) and 
maleic anhydride was added under constant monitoring of 
pH values. If necessary, Na2CO3 was added to stabilize the 
pH at 8.5–9.0. To detect successful maleylation, the free 
amino groups were determined as reported by Habeeb [41]. 
In brief, 100 µl of serial two-fold dilutions of the maleylated 
VLP-gB (mVLP-gB) and controls (non-maleylated VLP-gB, 
maleylated and non-maleylated BSA) were transferred to a 
96-well plate. Subsequently, 60 µl of 0.05 % picrylsulfonic 
acid (in 0.1 M NaHCO3) was added and incubated for 2 h at 
37 °C. Reactions were stopped by adding 50 µl SDS (10 %) and 
25 µl HCl (1 M) and absorbance was measured at 335 nm 
using the Epoch2 microplate reader (Biotek).
Electron microscopy
Concentrated VLPs were adsorbed to parlodion/carbon-
coated copper grids for 2 min. Grids were rinsed four times 
with PBS containing 10 % goat serum and subsequently 
incubated for 30 min at room temperature with the anti-Myc.
A7 antibody (Pierce, Thermo Fisher Scientific) diluted 1 : 50 
in PBS containing 1 % goat serum. Grids were rinsed five 
times with PBS containing 10 % goat serum and incubated 
for 30 min at room temperature with 10 nm diameter gold-
conjugated anti-mouse IgG (Sigma Aldrich, Merck) diluted 
1 : 50 in PBS containing 1 % goat serum followed by five 
washes with PBS and four washes with double distilled H2O. 
For the additional negative stain, grids were treated with 3 % 
uranyl acetate acid for a maximum of 20 s. Imaging was done 
using a TEM10 microscope (Zeiss) at 85 kV.
Immunofluorescence microscopy
LMH cells were grown on glass cover slips in 24-well plates. 
Then, 48 h after transfection with pcGag and pDgB and 
pDgG, respectively, cells were transferred and incubated at 
4 °C for 30 min with an anti-His antibody (SignalChem) diluted 
1:300 in RPMI supplemented with 2 % BSA. Cells were 
washed and fixated with 3 % paraformaldehyde. After 
washing three times with PBS, coverslips were incubated for 
45 min at room temperature with an Alexa Fluor 488-coupled 
secondary antibody (Thermo Fisher Scientific) diluted 1:1000 
in PBS containing 10 % goat serum and DAPI. After washing 
three times with PBS, coverslips were mounted on glass slides. 
Microscopic analysis was performed using an Olympus IX81 
inverted epifluorescence microscope.
Western blot analysis
Transfected LMH cells were lysed with RIPA buffer 48 h 
after transfection and protein concentration was determined 
employing a BCA protein assay kit (Pierce, Thermo Fisher 
Scientific). Same amounts of cell lysates and concentrated 
VLPs were loaded onto SDS gels containing 10 % poly-
acrylamide. A nitrocellulose membrane was used for blot-
ting. Proteins gB and gG were detected using an anti-HA 
antibody (clone16B12; Covance) and Gag was detected 
employing a polyclonal anti-MLV-p30 antibody (Icosagen). 
HRP-coupled secondary antibodies directed against rabbit 
IgG (Cell Signaling Technology) and mouse IgG (Santa Cruz 
Biotechnology), respectively, were used for visualization 
together with Clarity Western ECL Substrate (BioRad) and 
a ChemiDoc Imager (BioRad).
Protein expression and purification
LMH cells were cultivated in 10 cm dishes in Waymouth’s 
medium supplemented with 10 % FBS. Cells were transfected 
with pDgB or pDgG (each 15 µg per dish) using TransIT−2020 
(Mirus) according to the manufacturer’s instructions. 
HA-tagged gB or gG were purified employing the HA-tagged 
protein purification kit (MBL International Corporation). 
Cell lysates, samples from washing steps and the finally eluted 
protein were separated on an SDS gel containing 10 % poly-
acrylamide. A nitrocellulose membrane was used for blotting 
and was subsequently stained with colloidal gold (BioRad) 
to assess the purity of the recombinant protein preparations. 
Protein concentration was determined with the BCA protein 
assay kit (Pierce, Thermo Fisher Scientific).
Enzyme-linked immunosorbent assay
To quantify the displayed ILTV antigens, a 96-well plate was 
coated with serial dilutions of VLP-gB and VLP-gG, respec-
tively, in coating buffer (CB; 50 mM NaHCO3, pH 9.6). Serial 
dilutions of purified gB and gG were used as references. The 
plate was incubated for 1 h at room temperature followed by 
an overnight incubation at 4 °C. The plate was washed using 
washing buffer (PBS, 0.1 % Tween 20) and incubated for 1 h at 
room temperature with blocking buffer I (BBI; PBS, 5 % BSA, 
0.1 % Tween 20). Subsequently, the anti-Myc.A7 antibody 
(Pierce, Thermo Fisher Scientific) diluted 1 : 500 in BBI was 
added to the wells and incubated at room temperature for 
1 h. After thorough washing three times, an anti-mouse HRP 
antibody (Santa Cruz Biotechnology) diluted 1 : 1000 in BBI 
was added and incubated for 1 h at room temperature. Three 
washing steps were performed and TMB reagent (GenScript) 
was added for the detection of bound HRP-coupled antibodies 
and incubated for 30 min at room temperature. The reactions 
were stopped by addition of 2 N H2SO4 and absorbance was 
measured at 450 nm using the Epoch2 microplate reader 
(Biotek).
To detect gG-specific antibodies in chicken serum, 96-well 
plates were coated with 800 ng purified gG in coating buffer. 
After an overnight incubation at 4 °C, plates were washed 
using wash buffer II (0.5 M NaCl in PBS, pH 7.2, 0.05 % 
Tween 20) and incubated for 2 h at 37 °C employing blocking 
buffer II (BBII; PBS, 1 % BSA, 0.1 % Tween 20). All sera were 
diluted 1 : 100 in dilution buffer (wash buffer II, 1 % BSA), 
added to the plate and incubated for 1 h at room temperature. 
Plates were washed four times and incubated for 1 h at room 
temperature using an HRP-coupled anti-ChIgY antibody 
(ProSci) diluted 1 : 5000 in dilution buffer. Plates were washed 
four times and TMB reagent was added for the detection of 
bound HRP-coupled antibodies and incubated for 30 min at 
room temperature. The reactions were stopped by addition 
of 1 M H2SO4 and absorbance was measured at 450 nm using 
the Epoch2 microplate reader (Biotek).
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Animal experiments
For this study, fertilized eggs from Lohmann LSL-Classic 
laying hens (department’s own flock) were used. The parental 
animals were purchased from a Swiss poultry breeding 
company, and thus had been vaccinated against Marek’s 
disease, infectious bronchitis, infectious bursitis and avian 
encephalomyelitis. Commercial layers in Switzerland are also 
free from Newcastle disease (ND), ILT, Salmonella Enteritidis, 
pox, egg drop syndrome 1976, infectious coryza, Mycoplasma 
gallisepticum and Mycoplasma synoviae. The chickens were 
tested to be free from Salmonella and ILTV. Because commer-
cial laying hens are the main target for ILTV vaccination, it 
was decided to use this common chicken hybrid.
Fertilized eggs were incubated and at embryonic day (ED) 
18 randomly divided into three groups as shown in Table 2. 
Groups I to III comprised the study group gG and were vacci-
nated in ovo. Four eggs were injected with PBS (group I), seven 
eggs received plasmid pcDNA-ChIL-2-His [in PBS, DMSO 
50 % (v/v), incomplete Freud’s adjuvant 25 % (v/v); group 
II] and seven eggs were injected with plasmid pcDNA-ChIL-
2-His [in PBS, DMSO 50 % (v/v), incomplete Freud’s adjuvant, 
25 % (v/v)] and VLP-gG (group III). VLPs were injected into 
the amniotic cavity whereas plasmids were administered on 
top of the chorioallantoic membrane (CAM). One chick in 
group II did not hatch. To obtain a complete data set, this 
treatment was repeated in parallel with study group gB as 
shown in Table 2. Upon hatching, chicks were individually 
marked with leg bands and transferred to chicken isolators 
(TS Group Holland). On day 14 post-hatch (p.h.) chicks of 
groups I to III received a respective boost of PBS or plasmid 
pcDNA-ChIL-2-His or plasmid pcDNA-ChIL-2-His and 
VLP-gG, respectively, into the musculus iliotibialis lateralis.
Groups IV to VI comprised the study group gB without in 
ovo vaccination. Fertilized eggs were hatched, and chicks were 
transferred to chicken isolators, and randomly divided into 
three groups on day 14 p.h.: four chicks received injections 
of PBS (group IV), seven chicks received plasmid pcDNA-
ChIL-18-His (group V), and seven chicks received plasmid 
pcDNA-ChIL-18-His and mVLP-gB into the musculus ilioti-
bialis lateralis (group VI).
Immediately after hatching, animals were monitored every 
morning for signs of fitness. This visual examination was 
done by the same two people experienced in poultry health 
and behaviour in accordance with the recommendations 
of the Federation for Laboratory Animal Science Associa-
tions (FELASA) working group [42]. Three days post-hatch 
(DPH) and 2 days post-vaccination, animals were moni-
tored twice a day (morning and afternoon). According to 
the observations, the vitality score was determined to enable 
an objective assessment of the animals’ wellbeing. Vitality 
score criteria were as follows: 0, normal; 1, for each of the 
following clinical signs: closed eyelids, ruffled feathers, 
increased breathing, separation from the group, limping. 
Scores were added and interpreted as: 0, normal; 1, mild 
pain or distress; ≥2, severe pain or distress (with euthanasia 
upon inspection). Weight was determined every 3–4 days, 
and in the same intervals blood samples were taken from 
the wing vein starting from day 8 p.h. (gG, groups I, II, III) 
or day 12 p.h. (gB, groups IV, V, VI). At the age of 35 days, 
chicks were euthanized and dissected. Relative weight gain 
was determined at the end of every week at 8, 15, 22, 29 and 
35 DPH by calculating the difference between the average 
weight per group of the current and the past week. The value 
of the respective past week was set as a reference to a value 
of 100 %.
Isolation of spleen lymphocytes
Spleen cells were isolated by removing the capsule and passing 
the spleen through a 70 µm pore size cell strainer (Fisher 
Scientific) into isolation medium (IM; RPMI 1640, 2 % FBS). 
The single cell suspension was transferred onto Histopaque 
1077 columns (Sigma Aldrich, Merck) and centrifuged for 
20 min at 600 g at room temperature. Cells at the interface 
were collected in PBS and centrifuged again for 10 min at 
300 g. After repeating the last step, spleen lymphocytes were 
collected in cultivation medium (CM; RPMI 1640, 10 % FBS, 
Table 2. Experimental design and treatments of the two study groups: gG and gB
In ovo (ED 18) 14 DPH
Group Treatment Amount* Treatment Amount*
gG I PBS 100 µl PBS 100 µl
II pcDNA-ChIL-2-His 60 µg/100 µl pcDNA-ChIL-2-His 60 µg/100 µl
Study group III pcDNA-ChIL-2-His
VLP-gG
60 µg/100 µl
300 µg/100 µl
pcDNA-ChIL-2-His
VLP-gG
60 µg
300 µg/100 µl
gB IV – PBS 100 µl
V – pcDNA-ChIL-18-His 60 µg/100 µl
VI – pcDNA-ChIL-18-His mVLP-gB 60 µg
250 µg/100 µl
*Amount per individual vaccination.
DPH, days post hatch; ED, embryonation day.
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50 µM beta-mercaptoethanol, 100 U ml−1 penicillin/strepto-
mycin), ready for further processing.
Enzyme-linked immunospot assay
Ninety-six-well filter plates (MAIPS4510, Merck Millipore, 
Merck) were pre-wetted with 35 % (v/v) ethanol for 30 s, 
followed by three washing steps with H2O, PBS and coating 
buffer (CB; 50 mM NaHCO3, pH 9.6), respectively. An anti-
ChINF-γ antibody (Ch. IFN-γ Cytoset, Invitrogen, Thermo 
Fisher Scientific) was added (0.4 µg per well) and incubated 
overnight at 4 °C. Plates were rinsed twice with blocking buffer 
III (BBIII; RPMI 1640, 2 % FBS, 50 µM beta-mercaptoethanol, 
100 U ml−1 penicillin/streptomycin) and incubated with BBIII 
for 1 h at 38 °C under 5 % CO2. BBIII was discarded and 5×105 
spleen lymphocytes in 100 µl CM were seeded per well. Cells 
were incubated in the presence of either culture medium or 
medium supplemented with one of the following stimulating 
reagents to a final volume of 200 µl per well: ionomycin (2.8 
µM) and phorbol 12-myristate 13-acetate (PMA; 0.65 µM), 
purified gB (4 µg) or ILTV strain 489 (m.o.i. 2). Cells were 
incubated for 48 h at 38 °C in a 5 % CO2 atmosphere. The 
supernatants were discarded and plates were rinsed twice with 
H2O and three times with wash solution (WS; PBS, 0.1 % 
Tween 20). Plates were incubated for 1 h at room tempera-
ture with a biotinylated anti-ChINF-γ antibody (Ch. IFN-γ 
Cytoset, Invitrogen, Thermo Fisher Scientific) diluted 1 : 310 
in BBII. After four rinses with WS, plates were incubated for 1 
h at room temperature with streptavidin-HRP diluted 1 : 1000 
in BBII. Subsequently, plates were washed five times with PBS 
and incubated for 40 min with Novex HRP Chromogenics 
Substrate (Thermo Fisher Scientific). After rinsing under 
running water, plates were air-dried and analysed with an 
AID ELISPOT reader (AID Autoimmun Diagnostika).
Fluorescence-activated cell scanning
Citrated blood samples (~500 µl) were mixed 1 : 2 with 
PBS and transferred onto Histopaque 1077 columns (Sigma 
Aldrich, Merck) and centrifuged for 20 min at 400 g at 
room temperature. Cells at the interface were collected into 
PBS and centrifuged again for 5 min at 400 g at 4 °C. Upon 
suspension of the cell pellet in FACS buffer (PBS, 2 % FBS, 
0.05 % NaN3), cells were counted and aliquoted at a concen-
tration of 5×105 cells/50 µl. Cells were kept at 4 °C and were 
analysed for the surface expression of CD3+, CD4+ and CD8+, 
respectively. Unstained cells served as negative controls. To 
facilitate compensation for spectral overlap, single stains were 
also performed. The FITC-coupled anti-ChCD3 antibody 
(Abcam) was used at a final concentration of 5 µg ml−1, the 
PE-coupled anti-ChCD4 antibody (Acris) was used at a final 
concentration of 0.2 µg ml−1, and the PE-coupled anti-ChCD8 
antibody ( antibodies- online. com) was applied at a final 
concentration of 0.5 µg ml−1. Cells were incubated for 45 min 
at 4 °C followed by centrifugation for 5 min at 400 g at 4 °C. 
Cells were washed with FACS buffer and centrifuged again. 
Upon fixation with 1 % paraformaldehyde for 10 min and a 
final centrifugation, cells were resuspended in FACS buffer 
and filtered through a 35 µm cell strainer into a polystyrene 
round bottom tube (Fisher Scientific). Samples were analysed 
using a FACS Canto (BD Bioscience) at the flow cytometry 
facility of the University of Zurich by acquiring 10 000 events 
in the lymphocyte gate. Data analysis was performed using 
the BD FACSDIVA (BD Bioscience) and the FlowJo, LLC 
software.
Statistical analysis
To calculate the number of animals needed to reveal signifi-
cant results, the software G*Power was used. Mean values, 
percentages, standard deviations and ANOVA variance test 
(single factor) results were determined using Excel.
RESuLTS
Expression of ChIL-2 and ChIL-18 in chicken LMH 
cells
The sequences of each chicken interleukin (ChIL-2, ChIL-
18) were cloned into expression vectors containing either the 
CMV promoter or the CAG promoter consisting of the CMV 
immediate early enhancer followed by the chicken beta actin 
(CBA) promoter and the rabbit beta globin intron. To examine 
potential variations in promoter-dependent expression, the 
respective plasmids were transfected into LMH cells and total 
RNA was analysed 48 h later using real-time RT-PCR. As 
shown in Table 3, Ct values did not differ significantly between 
ChIL-2 or -18 expressed from the CMV promoter or from the 
CAG promoter. In all further experiments described here, 
the ChIL-expression plasmids containing the CMV promoter 
were used.
Generation and characterization of VLPs
To achieve the display of ILTV gB and gG on the surface of 
VLPs, respectively, the corresponding coding regions were 
inserted into the pDisplay vector, encoding the murine immu-
noglobulin chain leader sequence as well as the transmem-
brane domain of the platelet-derived growth factor receptor 
(PDGFR), thereby facilitating transport through the secretory 
pathway and anchoring of the respective fusion protein in the 
plasma membrane. For gB, the coding region for the first 700 
aa was inserted, consequently depleting the transmembrane 
domain and the cytoplasmic tail at the C terminus. For gG, the 
Table 3. Threshold cycle (C
t
) values from real-time RT-PCRs performed in duplicate on total RNA extracted from transfected LMH cells
Interleukin ChIL-2 ChIL-18
Promoter Mock CMV CAG Mock CMV CAG
Ct nd/ 30.91 15.75/15.65 15.54/15.38 27.28/27.31 14.07/14.07 14.87/14.26
1019
Schädler et al., Journal of General Virology 2019;100:1013–1026
N-terminal signal sequence was removed and only the coding 
region for amino acid positions 30 to 292 was inserted into the 
expression vector (Fig. 1). Besides the pDisplay-encoded HA 
and Myc tags, the expressed fusion proteins described here 
harboured a His tag, which was introduced with the oligonu-
cleotides used to amplify the respective DNA fragments prior 
to insertion into the vector (compared in Table 1).
Surface expression of the resulting ILTV protein variants 
gB700 and gGΔ1–29 was verified by immunofluorescence 
staining of LMH cells transiently transfected with the respec-
tive expression constructs. To ensure surface staining, living 
cells were kept on ice during exposure to antibodies and 
thereafter fixed. As illustrated in Fig. 2 (a), both glycoproteins 
were readily detected.
To verify the expression of VLPs displaying gB700 and gGΔ1–
29, respectively, LMH cells were either transiently transfected 
with the respective ILTV glycoprotein variant expression 
plasmids only or co-transfected together with pcGag. As 
illustrated in Fig. 2b, lysates and concentrated supernatants of 
transfected cells were subjected to Western blotting analysis. 
Since pcGag encodes only the MLV Gag protein and not 
the viral protease, the anti-p30 antibody detected the Gag 
precursor protein p65 and not the capsid protein p30 in cell 
lysates and supernatants. Both ILTV glycoprotein variants 
were detected in cell lysates independent of the co-expression 
of Gag. As expected, gB700 and gGΔ1–29 revealed approxi-
mate molecular weights of 100 and 60 kDa, respectively. In 
contrast, both ILTV protein variants were detected only in 
supernatants that also contained Gag. This indicated incor-
poration of the ILTV protein variants into MLV Gag-formed 
VLPs. This observation was further supported by electron 
microscopy using immunogold-labelled antibodies specific 
for the Myc tag present in both viral protein variants. As 
shown in Fig. 2c, particle structures were detected in all VLP 
preparations. Gold particles located at the membrane of these 
particles were visualized in VLP-gB and VLP-gG preparations 
but not in controls consisting of ‘naked’ VLPs. This further 
substantiated the decoration of VLPs with both ILTV protein 
variants.
VLPs-gB were further modified by maleylation. To measure 
a successful reaction, the availability of free amino groups 
of VLPs-gB was analysed. As a control, BSA was maleylated 
in parallel. The relative amount of free amino groups of 
unmodified proteins decreased with increasing dilution. In 
contrast, the relative amount of free amino groups of the 
maleylated proteins was constant at a very low level, indi-
cating a successful maleylation of the proteins, as shown in 
Fig. 2d.
Fig. 2. ILTV glycoprotein variant expression and characterization of VLPs. (a) Surface expression of gB700 and gGΔ1–29 on transiently 
transfected LMH cells. Upper row: cell nuclei were stained with DAPI. Lower row: ILTV glycoproteins were visualized by immunfluorescence 
using anti-His antibodies. (b) Western blot analysis of cell lysates and supernatants of LMH cells transiently transfected with the 
indicated expression plasmids. MLV Gag was detected using anti-p30 antibodies. ILTV glycoproteins (GP) were detected using anti-HA 
antibodies. (c) Electron micrographs of VLPs displaying ILTV glycoprotein variants detected with gold-labelled anti-Myc tag antibodies. 
(d) Determination of free amino groups on maleylated VLP-gB (mVLP-gB) and control BSA.
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Tolerability of the vaccines
To identify potential adverse effects of the vaccine on the 
development and wellbeing of the chicken embryos or 
hatched chicks, several factors were taken into consideration, 
i.e. hatching rate, vitality score (indicating general health and 
wellbeing), sex ratio and weight gain.
The hatching rate of all in ovo injected individuals was 95 % 
(18 chicks out of 19 hatched; 18/19), including 4/4 (100 %) in 
the negative control group, which received only PBS (group I), 
6/7 (86 %) in the group being treated with plasmids encoding 
ChIL-2 (group II), and 7/7 (100 %) in animals receiving plas-
mids expressing ChIL-2 and VLPs (group III). As depicted 
in Fig. 3a and b, single chicks showed mild signs of distress 
mainly in the first few days after hatching reflected by a 
vitality score of 1. However, this was not related to a particular 
treatment but a result of post-hatching adaptation to a new 
environment and food uptake. On day 12 p.h., a mock treated 
chick (PBS) of the gB group was rated with a score of 1 due 
to peculiar sleepiness (closed eyelids) probably associated 
with blood sampling earlier that day. No unusual behaviour 
was detected on the following day. Score 1 was also attributed 
to a ChIL-18, mVLP-gB-treated chick as breathing difficul-
ties were observed. Examination of the chick revealed fibre 
originating from the bedding material stuck at the entrance of 
the larynx. Upon removal of the fibre, breathing normalized 
again. In summary, none of the clinical signs observed in the 
chicks could be attributed to vaccination.
The sex ratio in each group had – as expected for a layer hen 
line – a slight tendency towards more males as shown in 
Fig. 3c and as previously described [43].
Within the respective study groups, the weight of the chicks 
increased over time with no statistical significance between 
the different treatments (PBS, plasmid, plasmid and VLP) as 
shown in Fig. 4a , b. However and as illustrated in Fig. 4c, a 
difference was noted between the two study groups gB and gG 
concerning average weight gain per week. Although weight 
at hatch was comparable between all groups (on average 
39 g), weight gain during the first week was much higher 
for gB groups IV–VI, which almost doubling their weight 
compared to the gG groups, which only gained around 30 % 
of their initial weight. However, in week 2 the relative weight 
gain of the gG group reached the level of the gB group, and 
even exceeded them in weeks 3 and 4, leading to average 
weights within the gG group of 351 g that were about 10 % 
lower than the average weight of the gB group (393 g) after 
week 5.
Transcription of ChIL-2/-18 upon plasmid injection 
in ovo or i.m.
To promote a humoral or cellular immune response, plasmid 
encoded ChIL-2 or ChIL-18 were administered in addition 
to the respective VLPs. Expression of both interleukins was 
monitored by qRT-PCR at various time points after vaccina-
tion. No differences in ChIL-2 or ChIL-18 levels were detected 
in the blood (or any other investigated organ) of animals 
receiving plasmids expressing chicken interleukins compared 
to PBS-treated animals (data not shown).
Immune response to VLPs-gB
Application of ILTV gB-displaying VLPs – further modified 
by maleylation – and co-administration of plasmid encoded 
ChIL-18 aimed at inducing a cell-mediated immune response. 
To examine this, the IFN-γ response of spleen lymphocytes 
upon stimulation with different antigens was conducted. 
Three weeks after vaccination, at the age of 35 days, chicks 
were euthanized and spleens were processed for further 
analysis using an ELISPOT assay performed in triplicate. The 
average number of spots is depicted in Fig. 5a. Lymphocytes 
from all animal groups treated with PBS, ChIL-18, ChIL-18 
and mVLP-gB, respectively, responded to stimulation with 
ionomycin and PMA, used as a positive control. Nevertheless, 
no reaction was detected upon stimulation of the lymphocytes 
with ILTV or gB alone.
The IFN-γ response of spleen lymphocytes cannot be moni-
tored at multiple time points in one individual animal. Thus, 
the ratio of CD4+ to CD8+ T lymphocytes was determined 
Fig. 3. (a, b) Vitality scores of vaccinated and control chicks. (a) gB group, i.m. injection on day 14. (b) gG group, in ovo vaccination and 
i.m. booster vaccination on day 14. Bold, blood sampling; underlined, day of (booster) vaccination. (c) Ratio of female to male chicks in 
the respective groups.
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as an additional indicator of the cellular immune response. 
These values are depicted in Fig. 5b as box plots as well as 
the average of the three treatment groups including a corre-
sponding trend line. A treatment-independent increase in 
the ratio of CD4+ to CD8+ cells 2 days after vaccination (DPH 
16) was detected. At later time points, a decrease of the CD4+ 
to CD8+ ratio was observed. This decrease was slightly more 
pronounced in chicks vaccinated with ChIL-18 and mVLP-18.
Fig. 4. Weight development of chicks during the experimental period. (a) Weight development of chicks of the study group gB (b) and 
study group gG (c). Relative weight gain per week (lines) per individual treatment and average weight (bars) of the whole group.
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Immune response to VLPs-gG
Vaccination with VLP-gG and plasmid-encoded ChIL-2 
aimed at provoking a humoral immune response, which 
should prevent – in case of an ILTV infection – the 
gG-induced immune evasion mechanism. ILTV gG-specific 
antibodies were detected using ELISA. Results are depicted 
as box blots in Fig. 5c. At the first time point of measure-
ment (DPH 8) 11 days after in ovo vaccination, gG-specific 
antibodies were detected. Titres decreased on DPH 16 and 
reached background levels on DPH 22.
dISCuSSIon
The present pilot study describes the use of heterologous 
VLPs as a vaccination platform against ILTV in chickens. 
VLP-based poultry vaccines were mainly investigated in the 
context of avian influenza and ND and showed promising 
results such as high antigenicity and even protection from 
infection [44–46]. Most studies directly examine the protec-
tion that is conferred by a particular vaccine. For animal 
welfare reasons, this study focused first on determining the 
Fig. 5. Immune response. (a) IFN-γ ELISPOT responses to ILTV antigens. The total magnitude of IFN-γ ELISPOT responses is given for 
individual chicks. The ELISPOT assay was performed in triplicate. (b) Ratios of CD4+/ CD8+ T cells determined by FACS. (c) Humoral 
response in VLP-gG-vaccinated and control chicks. The antibody response was measured at various time points after in ovo prime and 
booster vaccination. The ELISA was conducted in duplicate and repeated twice.
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tolerability as well as the immune responses elicited upon 
vaccination.
Because MLV-based VLPs are enveloped with a membrane 
originating from the cells utilized for production, it was 
decided to generate the VLPs in a chicken cell line (LMH) 
to avoid immune reactions directed against heterologous 
host cell proteins. Expression levels of the ILTV glycoprotein 
variant-displaying VLPs in LMH cells was comparable to the 
productivity in the most frequently used human producer cell 
line 293T (data not shown).
The in ovo injection had no impact on hatching rate, which 
is on average between 85 and 95 % upon artificial incuba-
tion [47, 48] and ranged between 86 and 100 % in this study. 
Neither in ovo administration nor i.m. injection resulted in 
adverse effects in chicks as rated in the vitality score. No influ-
ence on the weight at hatch was observed. Notably, the weekly 
weight gain was reduced in the in ovo vaccinated gG group 
compared to the gB group receiving no treatment prior to 
hatch. Unfortunately, we did not find earlier reports exam-
ining the effect of in ovo mock injections in comparison to 
no manipulation at all. We assumed that the observed differ-
ence was not related to the vaccine but rather a result of the 
injection procedure as animals in the control groups (injec-
tion of PBS and plasmid encoding ChIL-2, respectively) also 
revealed a delayed weight gain. Another factor that could have 
contributed to the delayed weight gain is the different age of 
the breeders at the time of egg-laying [49] as the experiments 
with the two groups (gG, gB) were not conducted in parallel.
Previous experiments showed that ChIL-2 was detectable in 
blood, thymus and liver of 20-day-old embryos 2 days after 
administration of ChIL-2 expression plasmids through the 
CAM. In the current study, expression of ChIL-2 was detected 
when blood was analysed on day 8 p.h. (11 days after in ovo 
administration of the ChIL-2 expression plasmids) or at later 
time points (DPH: 16, 22, 25, 29, 35). However, no differ-
ences were observed between the control group (PBS) and 
groups who received the ChIL-2 expression plasmids. This 
might be due to an onset of endogenously produced ChIL-2, 
which can occur between days 2 and 4 p.h. [50]. The same 
was observed for the expression of ChIL-18: no difference 
was detected between the control group (PBS) and chickens 
that received the expression plasmid when analysed 2 days 
after i.m. administration on day 14. This could also be due to 
an early onset of constitutive ChIL-18 expression already on 
ED 12 and an increase immediately upon hatching [51]. For 
future experiments, a detection method needs to be utilized 
enabling the differentiation between endogenous and recom-
binant interleukins.
Various studies have indicated a particular importance of the 
cellular immunity to protect against ILTV infection [25–29]. 
This issue was addressed in the current study by maleylation 
of the gB-displaying VLPs and co-administration of plasmids 
mediating the expression of ChIL-18. Although thymocytes 
in the chicken embryo respond to mitogen stimulation as 
early as ED 14, these cells reach their full activation capacity 
at an age of about 2 weeks [52]. Thus, it was decided to apply 
the vaccine at a stage where it was more likely to elicit a robust 
cellular immune response. Nevertheless, a strong cellular 
immune response could not be detected. The ELISPOT 
assay did not reveal any IFN-γ response upon stimulation 
with the antigen. One potential reason for this might be the 
time point of sampling at 21 days post-vaccination, and thus, 
rather late compared to other vaccination studies describing 
sampling between 7 and 17 days post-vaccination [53–55]. 
To monitor the cellular immune response over time, the ratio 
of CD4+ to CD8+ T cells was determined by FACS. This ratio 
is an indicator for immune competence. Upon virus infec-
tion (or vaccination), cytotoxic T lymphocytes, which are 
largely CD8+, undergo massive expansion [56–58]. CD4+ T 
cells also expand, but their differentiation into subsets that 
possess distinct effector functions is more pronounced. The 
expansion phase lasts for about 2 weeks and peaks at about 1 
week after antigen exposure. Thus, virus infection is usually 
accompanied by a decreased CD4+/CD8+ T cell ratio. In 
healthy, non-vaccinated chickens the CD4+/CD8+ T cell ratio 
remains relatively constant even at different ages, but it can 
vary between different chicken lines and housing conditions. 
For specific pathogen-free chickens, lower ratios (between 
0.74 and 0.94) were found compared to different laying hen 
lines kept under regular housing conditions (Dekalb Delta 
hybrid: 1.2; outbred white leghorn chicken: 3.25) [59, 60]. 
In the current study, no statistically significant difference 
in CD4+/CD8+ ratio over time for control treated animals 
(PBS: 1.34±0.17, ChIL-18: 1.17±0.18) was observed. This is 
in accordance with previous studies reporting similar findings 
for chickens kept in regular environments. In contrast, the 
vaccinated chicks showed a slight trend towards an increase of 
CD8+ cells. This contradicts the results of an ILTV vaccination 
study published by Chen and colleagues, who detected an 
increase of the CD4+/CD8+ ratio and furthermore associated 
this increase with the conferred protection [61]. In contrast, 
protective vaccination against ND and fowl adenovirus, 
respectively, were reported to be a result of a decreased CD4+/
CD8+ ratio [62, 63].
To counteract the ILTV gG-induced immune evasion, this 
study aimed at inducing gG-specific antibodies using in ovo 
vaccination with gG-displaying VLPs and ChIL-2 expression 
constructs. To further increase the immune response, a booster 
vaccination was administered i.m. on day 14. On the first day of 
sampling (DPH 8, 11 days after vaccination), increased anti-gG 
antibody levels were detected. This was a promising result, as 
ILTV gG seems to be only weakly antigenic [64]. The success 
of the described approach is probably due to the high density of 
antigens decorated on the surface of the membrane-enveloped 
VLPs. The elicited anti-gG antibody levels decreased over 
time and reached background levels on day 22 (1 week after 
the boost). Surprisingly, the boost did not lead to an increased 
or at least constant antibody titre. The detected effect on the 
cellular immune response was also weaker than expected and 
was probably a result of the comparably low amount of antigen 
used. Most vaccines currently administered in ovo are either 
replication competent attenuated life vaccines or vector-derived 
vaccines. The replication incompetence of VLPs, which is an 
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advantage regarding safety, might be a drawback regarding the 
induction of a robust immune response. Yet various studies 
have shown that a single in ovo vaccination with a replication-
incompetent reagent such as outer membrane vesicles of gram-
negative bacteria or antigen–antibody complexes (AACs) can 
induce at least an antibody response [65, 66]. Nevertheless, we 
propose a higher dosage for the i.m. application, which should 
be determined according to the actual body weight at the time 
of injection. The average weight of a layer chicken embryo at ED 
18 is 22 g, and thus the injected amount of vaccine corresponds 
to 14 µg g−1 body weight (bw). In contrast, the injected amount 
of VLP in the 14-day-old chicks was around 2–3 µg g−1 bw for 
VLP-gB or VLP-gG respectively. Furthermore, analysis of the 
cellular immune response by ELISPOT should be conducted 
at two time points closer to the time of vaccination, e.g. 7 and 
14 days post-injection as in earlier vaccination studies [53, 54].
In summary, the MLV-derived VLPs displaying ILTV glyco-
protein variants were well tolerated and were able to induce a 
detectable immune response. Thus, this new approach could 
initiate the further development of ILTV vaccines and the 
generation of safer vaccines for poultry in general.
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